Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28767868 | 0.62 | POLB (0.37) | CNR2ALOX15HRH3HTT | |
| SCHEMBL31065977 | 0.61 | TSHR (0.38) | TSHRHTT | |
| SCHEMBL15882625 | 0.61 | SMN1; SMN2 (0.45) | ALOX15HRH3 | |
| SCHEMBL4374019 | 0.60 | TSHR (0.37) | TSHRHTT | |
| SCHEMBL572678 | 0.60 | PDK2 (0.46) | — | |
| SCHEMBL22304750 | 0.60 | KCNH2 (0.36) | CNR2ALOX15HRH3 | |
| SCHEMBL9123485 | 0.59 | HRH3 (0.42) | ALOX15HRH3TSHRHSD17B10HTT | |
| SCHEMBL3185991 | 0.58 | SIGMAR1 (0.38) | CNR2ALOX15HRH3HSD17B10HTT | |
| SCHEMBL31346843 | 0.58 | NR1H2 (0.44) | — | |
| SCHEMBL5376068 | 0.57 | SMN1; SMN2 (0.59) | HRH3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695178-B2 | 6-(2-pyridyl)-7,8-dihydro-5H-pyrido[4,3-D]pyrimidine analogs as hedgehog pathway signaling inhibitors and therapeutic applications thereof | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2017-07-04 | — | — | US | disclosed |
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SUZHOU KINTOR PHARMACEUTICALS, INC. (CN) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024095-A1 | HEDGEHOG PATHWAY SIGNALING INHIBITORS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | CNR2 1305/4885ALOX15 2996/4885HRH3 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.